ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -79 مورد

Trabectedin: Drug information

Trabectedin: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Trabectedin: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Yondelis
Brand Names: Canada
  • Yondelis
Pharmacologic Category
  • Antineoplastic Agent, Miscellaneous
Dosing: Adult

Safety: Prior to each treatment cycle, ANC should be ≥1,500/mm3, platelets ≥100,000/mm3 total bilirubin ≤ ULN, and alkaline phosphatase, ALT, AST, and CPK ≤2.5 times ULN. Administer dexamethasone 20 mg IV 30 minutes prior to each infusion to minimize hepatotoxicity.

Clinical considerations: Trabectedin is associated with a moderate emetic potential (Ref); antiemetics are recommended to prevent nausea and vomiting.

Ovarian cancer, relapsed, platinum sensitive

Ovarian cancer, relapsed, platinum sensitive (off-label use): IV: 1.1 mg/m2 over 3 hours every 3 weeks (in combination with doxorubicin liposomal); continue as long as clinical benefit is demonstrated or until disease progression or confirmed complete response or for 2 or more cycles beyond complete response (Ref). Delay treatment and/or reduce the trabectedin dose (to 0.9 mg/m2, then to 0.75 mg/m2) for toxicities (doxorubicin liposomal may also require modification); consider discontinuing if a second dose reduction is not tolerated (Ref).

Soft tissue sarcoma, unresectable/metastatic liposarcoma or leiomyosarcoma

Soft tissue sarcoma, unresectable/metastatic liposarcoma or leiomyosarcoma:

Previously treated unresectable/metastatic liposarcoma or leiomyosarcoma : IV: 1.5 mg/m2 as a continuous infusion over 24 hours once every 3 weeks; continue until disease progression or unacceptable toxicity (Ref).

Previously untreated unresectable/metastatic leiomyosarcoma (off-label use/combination) : IV: 1.1 mg/m2 over 3 hours once every 3 weeks (in combination with doxorubicin and pegfilgrastim) for a maximum of 6 combination cycles, followed by single-agent trabectedin maintenance therapy of 1.1 mg/m2 over 3 hours once every 3 weeks until disease progression or unacceptable toxicity for up to a maximum of 17 maintenance cycles (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl ≥30 mL/minute: No dosage adjustment is necessary.

CrCl <30 mL/minute or end-stage kidney disease: There is no dosage adjustment provided in the manufacturer's labeling (effects are unknown); however, no need for dosage adjustment is expected (Ref).

Hemodialysis: Hemodialysis is not expected to enhance elimination of trabectedin. No need for dosage adjustment is expected (Ref).

Dosing: Liver Impairment: Adult

Hepatic impairment prior to treatment (per the manufacturer's labeling ):

Mild impairment (bilirubin >1 to 1.5 times ULN and any AST or ALT): No initial dosage adjustment necessary.

Moderate impairment (bilirubin >1.5 to 3 times ULN and AST or ALT <8 times ULN): Reduce dose from 1.5 mg/m2 to 0.9 mg/m2.

Severe impairment: (bilirubin >3 times ULN and any AST or ALT): Do not administer.

Hepatotoxicity during treatment:

Recommended dose reduction levels in patients with mild or moderate hepatic impairment at baseline (once a dose is reduced it should not be increased in subsequent cycles):

Mild impairment:

First dose reduction: 1.2 mg/m2 once every 3 weeks.

Second dose reduction: 1 mg/m2 once every 3 weeks.

Moderate impairment:

First dose reduction: 0.6 mg/m2 once every 3 weeks.

Second dose reduction: 0.3 mg/m2 once every 3 weeks.

Total bilirubin >ULN: Delay dose for up to 3 weeks and reduce the next dose by one dose level

AST or ALT >2.5 times ULN: Delay dose for up to 3 weeks

AST or ALT >5 times ULN during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level

Alkaline phosphatase >2.5 times ULN: Delay dose for up to 3 weeks and reduce the next dose by one dose level

Severe liver dysfunction (bilirubin 2 times ULN and AST or ALT 3 times ULN and alkaline phosphatase <2 times ULN in prior treatment cycle in patients with normal hepatic function at baseline): Permanently discontinue trabectedin.

Exacerbation of hepatic dysfunction in patients with preexisting moderate impairment: Permanently discontinue trabectedin.

Adverse reactions with trabectedin administered at 1 mg/m2 (in patients with normal hepatic function or preexisting mild hepatic impairment) or at 0.3 mg/m2 (in patients with preexisting moderate hepatic impairment) and requiring further dose reduction: Permanently discontinue trabectedin.

Dosing: Obesity: Adult

American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m2: Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2 (Ref). Note: According to the prescribing information, if a dose is reduced due to toxicity, do not re-escalate the dose.

Dosing: Adjustment for Toxicity: Adult

Soft tissue sarcoma:

Recommended dose reduction levels (once a dose is reduced it should not be increased in subsequent cycles):

First dose reduction: 1.2 mg/m2 once every 3 weeks

Second dose reduction: 1 mg/m2 once every 3 weeks

Hematologic toxicity:

ANC <1,500/mm3: Delay trabectedin dose for up to 3 weeks

ANC <1,000/mm3 with fever or infection or <500/mm3 lasting >5 days during prior cycle: Delay trabectedin dose for up to 3 weeks and reduce the next dose by one dose level

Platelets <100,000/mm3: Delay trabectedin dose for up to 3 weeks

Platelets <25,000/mm3 during prior cycle: Delay trabectedin dose for up to 3 weeks and reduce the next dose by one dose level

Nonhematologic toxicity:

Capillary leak syndrome: Permanently discontinue trabectedin and manage as clinically appropriate.

Cardiotoxicity, grade 3 or 4 cardiac adverse events indicative of cardiomyopathy or decreased left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN): Permanently discontinue trabectedin.

Creatine phosphokinase >2.5 times ULN: Delay trabectedin dose for up to 3 weeks

Creatine phosphokinase >5 times ULN during prior cycle: Delay trabectedin dose for up to 3 weeks and reduce the next dose by one dose level

Persistent adverse events requiring a delay of more than 3 weeks: Permanently discontinue trabectedin.

Rhabdomyolysis: Permanently discontinue trabectedin.

Other nonhematologic toxicity: Grade 3 or 4: Delay trabectedin dose for up to 3 weeks and reduce the next dose by one dose level

Adverse reactions with trabectedin administered at 1 mg/m2 (in patients with normal hepatic function or preexisting mild hepatic impairment) or 0.3 mg/m2 (in patients with preexisting moderate hepatic impairment; refer to dosing in hepatic impairment) and requiring further dose reduction: Permanently discontinue trabectedin.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Peripheral edema (28%)

Endocrine & metabolic: Hypoalbuminemia (63%)

Gastrointestinal: Constipation (37%), decreased appetite (37%), diarrhea (35%), nausea (75%), vomiting (46%)

Hematologic & oncologic: Anemia (96%; grades 3/4: 19%), neutropenia (66%; grades 3/4: 43%), thrombocytopenia (59%; grades 3/4: 21%)

Hepatic: Hyperbilirubinemia (13%), increased serum alanine aminotransferase (90%), increased serum alkaline phosphokinase (70%), increased serum aspartate aminotransferase (84%)

Nervous system: Fatigue (≤69%), headache (25%), insomnia (15%), malaise (≤69%)

Neuromuscular & skeletal: Arthralgia (15%), asthenia (≤69%), increased creatine phosphokinase in blood specimen (32% to 33%), myalgia (12%)

Renal: Increased serum creatinine (46%)

Respiratory: Dyspnea (25%)

1% to 10%:

Cardiovascular: Cardiomyopathy (6%), pulmonary embolism (<10%)

Gastrointestinal: Stomatitis (<10%)

Hematologic & oncologic: Febrile neutropenia (5%)

Hepatic: Hepatic injury (1%)

Infection: Neutropenic sepsis (≤3%)

Nervous system: Hypoesthesia (<10%), paresthesia (<10%), peripheral neuropathy (<10%)

Postmarketing:

Cardiovascular: Capillary leak syndrome

Neuromuscular & skeletal: Rhabdomyolysis

Contraindications

Known, severe hypersensitivity (including anaphylaxis) to trabectedin or any component of the formulation.

Canadian labeling: Additional contraindications (not in the US labeling): Active serious or uncontrolled infection; breastfeeding.

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia commonly occur; neutropenic fever and neutropenic sepsis (with fatalities) have been reported. The median onset for first occurrence of grade 3/4 neutropenia was 16 days (range: 8 days to ~10 months) and median time to recovery was 13 days (range: 3 days to ~2 months).

• Capillary leak syndrome: Capillary leak syndrome (CLS) has been reported, including serious cases resulting in death. Symptoms include hypotension, edema, and hypoalbuminemia.

• Cardiovascular events: Cardiomyopathy, including HF, decreased ejection fraction, diastolic dysfunction, or right ventricular dysfunction, has been observed; some events were grades 3 and 4. The median time to development of grades 3 and 4 cardiomyopathy was ~5 months (range: 1 to 15 months). Risk of cardiac dysfunction may be increased in patients with left ventricular ejection fraction (LVEF) below lower limit of normal, prior cumulative (lifetime) anthracycline dose ≥300 mg/m2, age ≥65, or history of cardiovascular disease. Permanently discontinue treatment for grade 3 or 4 cardiac events indicative of cardiomyopathy or for LVEF decreased below the lower limit of normal. Patients with a history of New York Heart Association class II, III, or IV heart failure or abnormal LVEF were excluded from the sarcoma study.

• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Infuse through a central line. Avoid extravasation. Extravasation of trabectedin with subsequent tissue necrosis requiring debridement has been reported; evidence of necrosis may be delayed up to 1 week after extravasation. There are no specific antidotes for trabectedin extravasation.

• Hepatotoxicity: Hepatotoxicity (including hepatic failure) may occur with trabectedin. Grade 3 and 4 LFT elevations (AST, ALT, total bilirubin, or alkaline phosphatase) occurred in over one-third of patients. The median onset for grade 3/4 ALT or AST elevations was 29 days (range: 3 days to 11.5 months) and the median time to resolution was 13 days (range: 4 days to ~4 months); some patients experienced complete resolution. Drug-induced liver injury (ALT or AST elevation >3 times ULN, alkaline phosphatase <2 times ULN, and total bilirubin ≥2 times ULN) and ALT or AST elevations >8 times ULN have been reported. Premedication with dexamethasone (4 mg twice daily the day prior to administration) has been reported to reduce the incidence of hepatotoxicity (Grosso 2006). Patients with bilirubin above the ULN or AST or ALT >2.5 times the ULN were excluded from the sarcoma clinical trial.

• Hypersensitivity: Symptoms of hypersensitivity reactions have been reported.

• Rhabdomyolysis: Trabectedin may cause rhabdomyolysis and musculoskeletal toxicity (some fatal). Creatine phosphokinase (CPK) elevations occurred in nearly one-third of patients receiving trabectedin; grade 3 and 4 CPK elevations, some complicated by renal failure, occurred. The median time to first occurrence of grade 3 or 4 CPK elevation was 2 months (range: 1 to 11.5 months) and the median time to complete resolution was 14 days (range: 5 to 30 days).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Yondelis: 1 mg (1 ea)

Generic Equivalent Available: US

No

Pricing: US

Solution (reconstituted) (Yondelis Intravenous)

1 mg (per each): $4,427.21

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Yondelis: 0.25 mg (1 ea); 1 mg (1 ea)

Administration: Adult

Trabectedin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Ref).

IV: Infuse through a central line with a 0.2 micron polyethersulfone filter. Infusion must be completed within 30 hours of reconstitution. Premedicate with a corticosteroid (eg, dexamethasone 20 mg IV) 30 minutes prior to treatment; additional antiemetics may be needed.

Soft tissue sarcoma:

Single-agent therapy: Infuse as a continuous infusion over 24 hours.

Off-label combination therapy with doxorubicin: Administer doxorubicin first, followed by trabectedin infused over 3 hours (Ref).

Ovarian cancer (off-label use): Combination therapy with doxorubicin liposomal: Administer doxorubicin liposomal first (flush line with D5W) then follow with trabectedin infusion over 3 hours (Ref).

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207953s004lbl.pdf#page=20, must be dispensed with this medication.

Use: Labeled Indications

Soft tissue sarcoma, unresectable or metastatic liposarcoma or leiomyosarcoma: Treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma) in patients who have received a prior anthracycline-containing regimen.

Use: Off-Label: Adult

Ovarian cancer, relapsed, platinum sensitive

Medication Safety Issues
Sound-alike/look-alike issues:

Trabectedin may be confused with lurbenectedin.

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

Metabolism/Transport Effects

Substrate of CYP3A4 (Major), P-glycoprotein (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Alcohol (Ethyl): May increase hepatotoxic effects of Trabectedin. Risk X: Avoid

Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of BCG Products. Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Cytotoxic Chemotherapy) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor

COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of COVID-19 Vaccine (Subunit). Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of Trabectedin. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Trabectedin. Risk X: Avoid

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Trabectedin. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of Trabectedin. Risk X: Avoid

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

HMG-CoA Reductase Inhibitors (Statins): May increase myopathic (rhabdomyolysis) effects of Trabectedin. Risk C: Monitor

Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Inebilizumab. Risk C: Monitor

Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy. Risk D: Consider Therapy Modification

Lenograstim: Antineoplastic Agents may decrease therapeutic effects of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider Therapy Modification

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Lipegfilgrastim: Antineoplastic Agents may decrease therapeutic effects of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider Therapy Modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Ocrelizumab. Risk C: Monitor

Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Ofatumumab. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Palifermin: May increase adverse/toxic effects of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Risk D: Consider Therapy Modification

Phenobarbital-Primidone: May decrease serum concentration of Trabectedin. Risk C: Monitor

Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Piperacillin: May increase hypokalemic effects of Antineoplastic Agents. Risk C: Monitor

Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Sphingosine 1-Phosphate (S1P) Receptor Modulators: May increase immunosuppressive effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk C: Monitor

St John's Wort: May decrease serum concentration of Trabectedin. Risk X: Avoid

Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Ublituximab. Risk C: Monitor

Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may decrease therapeutic effects of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to starting chemotherapy when possible. Patients vaccinated less than 14 days before or during chemotherapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Cytotoxic Chemotherapy) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Reproductive Considerations

Verify pregnancy status prior to treatment in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 2 months after the last trabectedin dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 5 months after the last trabectedin dose.

Pregnancy Considerations

Based on the mechanism of action, trabectedin may cause fetal harm if administered during pregnancy.

Breastfeeding Considerations

It is not known if trabectedin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during trabectedin treatment.

Monitoring Parameters

CBC with differential (baseline, prior to each dose, and periodically throughout treatment cycles); total bilirubin (prior to each cycle; more frequently if clinically indicated), ALT, AST, and alkaline phosphatase (prior to each dose; more frequently if clinically indicated); renal function (baseline and during treatment); CPK (prior to each dose). Evaluate pregnancy status (prior to treatment in patients who could become pregnant). Evaluate LVEF via MUGA or echocardiogram (baseline and every 2 to 3 months until trabectedin is discontinued). Monitor for signs/symptoms of capillary leak syndrome and hypersensitivity reactions; monitor infusion site for signs/symptoms of extravasation.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Mechanism of Action

Trabectedin is a marine-derived compound (alkylating agent) which blocks the cell cycle at the G2/M phase by covalently binding to the minor DNA groove, bending the helix toward the major groove and altering DNA transcription (Garcia-Carbonero 2005). Affects activity of DNA binding proteins, transcription factors and DNA repair mechanism, leading to cell death.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vdss: >5,000 L

Protein binding: ~97%; to plasma proteins

Metabolism: Extensively hepatic; via CYP3A4

Half-life elimination: ~175 hours

Excretion: Feces (58%; only negligible amounts as unchanged drug); urine (6%; only negligible amounts as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Following a single dose of 0.58 mg/m2 or 0.9 mg/m2 in patients with moderate hepatic impairment (total bilirubin >1.5 to 3 times ULN and AST and ALT <8 times ULN), trabectedin AUC increased by 97% (90% CI: 20%, 222%) compared with patients with normal liver function who received a single dose of 1.3 mg/m2.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Yondelis;
  • (AR) Argentina: Yondelis;
  • (AT) Austria: Yondelis;
  • (AU) Australia: Yondelis;
  • (BE) Belgium: Trabectedin ever pharma | Trabectedine teva | Yondelis;
  • (BG) Bulgaria: Yondelis;
  • (CH) Switzerland: Yondelis;
  • (CL) Chile: Yondelis;
  • (CO) Colombia: Yondelis;
  • (CZ) Czech Republic: Trabectedin ever pharma | Yondelis;
  • (DE) Germany: Yondelis;
  • (EC) Ecuador: Yondelis;
  • (EE) Estonia: Yondelis;
  • (EG) Egypt: Yondelis;
  • (ES) Spain: Trabectedin teva | Trabectedina ever pharma | Yondelis;
  • (FI) Finland: Trabectedin ever pharma | Yondelis;
  • (FR) France: Trabectedine teva | Yondelis;
  • (GR) Greece: Trabectedin/teva | Yondelis;
  • (HK) Hong Kong: Yondelis;
  • (HR) Croatia: Yondelis;
  • (HU) Hungary: Trabectedin teva | Yondelis;
  • (IE) Ireland: Yondelis;
  • (IN) India: Trabec | Yondelis;
  • (IT) Italy: Trabectedina teva | Yondelis;
  • (JP) Japan: Yondelis;
  • (KR) Korea, Republic of: Yondelis;
  • (KW) Kuwait: Yondelis;
  • (LB) Lebanon: Yondelis;
  • (LT) Lithuania: Yondelis;
  • (LV) Latvia: Yondelis;
  • (MX) Mexico: Yondelis;
  • (MY) Malaysia: Yondelis;
  • (NL) Netherlands: Trabectedine teva | Yondelis;
  • (NO) Norway: Yondelis;
  • (NZ) New Zealand: Yondelis;
  • (PH) Philippines: Yondelis;
  • (PL) Poland: Trabectedin ever pharma | Yondelis;
  • (PR) Puerto Rico: Yondelis;
  • (PT) Portugal: Yondelis;
  • (PY) Paraguay: Yondelis;
  • (QA) Qatar: Yondelis;
  • (RO) Romania: Trabectedin ever pharma | Trabectedin teva | Yondelis;
  • (RU) Russian Federation: Yondelis;
  • (SA) Saudi Arabia: Yondelis;
  • (SE) Sweden: Trabectedin ever pharma | Trabectedin teva | Yondelis;
  • (SG) Singapore: Yondelis;
  • (SI) Slovenia: Trabektedin teva | Yondelis;
  • (SK) Slovakia: Trabectedin teva;
  • (TH) Thailand: Yondelis;
  • (TN) Tunisia: Yondelis;
  • (TR) Turkey: Yondelis;
  • (TW) Taiwan: Yondelis;
  • (UY) Uruguay: Yondelis;
  • (ZA) South Africa: Yondelis
  1. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793. [PubMed 26371143]
  2. Garcia-Carbonero R, Supko JG, Maki RG, et al, “Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study,” J Clin Oncol, 2005, 23(24):5484-92. [PubMed 16110008]
  3. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  4. Griggs JJ, Mangu PB, Anderson H, et al, “Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,” J Clin Oncol, 2012, 30(13):1553-61. [PubMed 22473167]
  5. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42(10):1484-1490. [PubMed 16737808]
  6. Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195. doi:10.1016/j.esmoop.2023.102195 [PubMed 38458657]
  7. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 [PubMed 32658626]
  8. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  9. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  10. Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7 [PubMed 30942181]
  11. Monk BJ, Herzog TJ, Kaye SB, et al, “Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer,” J Clin Oncol, 2010, 28(19):3107-14. [PubMed 20516432]
  12. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361-2368. doi:10.1016/j.ejca.2012.04.001 [PubMed 22541893]
  13. Ovesen JL, Sammons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  14. Pautier P, Italiano A, Piperno-Neumann S, et al; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022;23(8):1044-1054. doi:10.1016/S1470-2045(22)00380-1 [PubMed 35835135]
  15. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” Ann Oncol, 2012, 23(Suppl 7):167-173. [PubMed 22997449]
  16. Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39-48. [PubMed 20643862]
  17. Theman TA, Hartzell TL, Sinha I, et al, “Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage,” J Clin Oncol, 2009, 27(33):e198-200. [PubMed 19805684]
  18. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
  19. Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products; June 2020.
  20. Yondelis (trabectedin) [product monograph]. Kirkland, Quebec, Canada: Valeo Pharma Inc; May 2020.
Topic 9513 Version 309.0